Binding of the Sialic Acid-binding Lectin, Siglec-9, to the Membrane Mucin, MUC1, Induces Recruitment of β-catenin and Subsequent Cell Growth
Overview
Authors
Affiliations
Because MUC1 carries a variety of sialoglycans that are possibly recognized by the siglec family, we examined MUC1-binding siglecs and found that Siglec-9 prominently bound to MUC1. An immunochemical study showed that Siglec-9-positive immune cells were associated with MUC1-positive cells in human colon, pancreas, and breast tumor tissues. We investigated whether or not this interaction has any functional implications for MUC1-expressing cells. When mouse 3T3 fibroblast cells and a human colon cancer cell line, HCT116, stably transfected with MUC1cDNA were ligated with recombinant soluble Siglec-9, β-catenin was recruited to the MUC1 C-terminal domain, which was enhanced on stimulation with soluble Siglec-9 in dose- and time-dependent manners. A co-culture model of MUC1-expressing cells and Siglec-9-expressing cells mimicking the interaction between MUC1-expressing malignant cells, and Siglec-9-expressing immune cells in a tumor microenvironment was designed. Brief co-incubation of Siglec-9-expressing HEK293 cells, but not mock HEK293 cells, with MUC1-expressing cells similarly enhanced the recruitment of β-catenin to the MUC1 C-terminal domain. In addition, treatment of MUC1-expressing cells with neuraminidase almost completely abolished the effect of Siglec-9 on MUC1-mediated signaling. The recruited β-catenin was thereafter transported to the nucleus, leading to cell growth. These findings suggest that Siglec-9 expressed on immune cells may play a role as a potential counterreceptor for MUC1 and that this signaling may be another MUC1-mediated pathway and function in parallel with a growth factor-dependent pathway.
Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy.
Tong X, Dong C, Liang S J Cancer. 2024; 15(1):54-67.
PMID: 38164273 PMC: 10751670. DOI: 10.7150/jca.88261.
Chan C, Lustig M, Jansen J, Garcia Villagrasa L, Raymakers L, Daamen L Cancers (Basel). 2023; 15(13).
PMID: 37444515 PMC: 10341145. DOI: 10.3390/cancers15133405.
Wielgat P, Rogowski K, Czarnomysy R, Wawrusiewicz-Kurylonek N, Narejko K, Bielawski K Int J Mol Sci. 2023; 24(6).
PMID: 36982588 PMC: 10057974. DOI: 10.3390/ijms24065512.
Zhao F, Tian H, Wang Y, Zhang J, Liu F, Fu L Cancer Immunol Immunother. 2023; 72(6):1835-1851.
PMID: 36688997 PMC: 10198857. DOI: 10.1007/s00262-022-03364-5.
The multifaceted role of MUC1 in tumor therapy resistance.
Jin W, Zhang M, Dong C, Huang L, Luo Q Clin Exp Med. 2022; 23(5):1441-1474.
PMID: 36564679 DOI: 10.1007/s10238-022-00978-y.